Madrigal Pharmaceuticals (MDGL) PT Raised to $510 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Thomas Smith raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $510.00 (from $430.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
